| A2352 | Acetylcholine Receptor α1, Fragment 129-145 Amino acids 129-145 of human, bovine, rat, and mouse sequence, ≥93% (HPLC) | | |
| |
| A8352 | Adenosine Transporter Receptor human membrane suspension | Membranes suspended in 50 mM Tris-HCl containing10% sucrose, pH 7.4. Actual concentration and specific binding capacity are provided with each lot.
| |
| |
| A213 | α2A-Adrenergic Receptor human recombinant, expressed in Sf9 cells, membrane suspension | | |
| |
| A6728 | β1-Adrenergic Receptor preparation human | Membranes suspended in 50 mM Tris-HCl containing 12 mM MgCl2 and 2 mM EDTA, pH 7.4. Actual concentration and specific binding capacity are provided with each lot.
| |
| |
| A8602 | Angiotensin II Receptor, Type 1 human membrane suspension | Membranes suspended in 50 mM TRIS-HCl containing10% glycerol 100 mM NaCl, 1 mM MgCl2, 0.1% BSA, 0.1 mM bacitracin, pH 7.2. Actual concentration and specific binding capacity are provided with each lot.
| |
| |
| A7231 | AZ11645373 ≥98% (HPLC), solid | AZ11645373 is a selective and potent human P2X7 purinoceptor antagonist. KB values range from 5-20 nM for human P2X7 receptor inhibition. It is 500-fold less effective ats an inhibitor of rat P2X7 receptor responses.
| |
| |
| C7743 | CHPG ≥98% (HPLC), white solid | CHPG is a selective, potent mGluR5 agonist. CHO cells expressing mGluR5 (but not those expressing mGluR1) are activated by CHPG. In vivo, CHPG stimulates thalamic neurons and is antagonized by MPEP (selective mGluR5 antagonist); CHPG potentiates NMDA and AMPA responses in spinal cord and produces oscillations in intracellular calcium in dorsal root ganglion cells.
| |
| |
| D2439 | D4.2 Dopamine Receptor human recombinant, expressed in Sf9 cells, membrane suspension | | |
| |
| D9071 | Donitriptan monohydrochloride ≥98% (HPLC) | Donitriptan is a potent, selective 5-HT1B/1D agonist.
| |
| |
| D4446 | Dopamine D1 Receptor human recombinant, expressed in HEK 293 cells, membrane suspension | Membranes are suspended in 50 mM TRIS-HCl containing 10 mM MgCl2, 1.5 mM CaCl2, 1mM EDTA, 5 mM KCl, 10% glycerol, (pH 7.4 at 25 °C).
| |
| |
| D181 | D3 Dopamine Receptor from rat recombinant, expressed in Escherichia coli, membrane suspension | | |
| |
| E9658 | Enalaprilat dihydrate ≥98% (HPLC) | Enalaprilat is an inhibitor of angiotensin converting enzyme (ACE), antihypertensive, and a Bradykinin B1 receptor activator. Enalaprilat has nM potency versus ACE and also activates B1 receptors to release NO.
| |
| |
| S177 | 5-HT7 Serotonin Receptor human recombinant, expressed in CHO cells, membrane suspension | | |
| |
| M2946 | Mosapride citrate salt dihydrate | 5-HT4 receptor agonist and 5-HT3 receptor antagonist
| |
| |
| N4036 | Neuropeptide Y Subtype 2 Receptor human membrane suspension | Membranes suspended in 50 mM Tris-HCl containing 5 mM MgCl2, 0.1% BSA, and 10% glycerol, pH 7.7. Actual concentration and specific binding capacity are provided with each lot.
| |
| |
| T180 | NK2 Tachykinin Receptor human recombinant, expressed in CHO cells, membrane suspension | | |
| |
| P0043 | PNU-120596 ≥98% (HPLC) | An allosteric modulator of α7 nicotinic receptors, N-(5-chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholinePNU-120596 is a positive allosteric modulator selective for the α7 nicotinic acetylcholine receptor.1 PNU-120596 produces no detectable change in currents mediated by α4β2, α3β4, α9α10 nAChRs. It increases channel mean open time, but does not affect ion selectivity. It does not bind at the agonist binding site, but induces conformational changes similar to the natural effector.1
| |
| |
| R4282 | RF9 trifluoroacetate salt ≥97% (HPLC) | RF9 is a neuropeptide FF receptor antagonist. NPFF is a member of the FMRFamide (Phe-Met-Arg-PheNH2) family of neuropeptides, which are implicated in nociception and regulation of opioid analgesia. NPFF exhibits antiopioid activity (hyperalgesia). NPFF antagonists are expected to improve the therapeutic efficacy of opioids for treatment of chronic pain. The affinity of RF9 for NPFF1R and NPFF2R is 58 and 75 nM, respectively. RF9 acts as a potent competitive antagonist of NPFF at NPFF2R RF9 exhibits no agonist activity in GTPgS assays.
| |
| |
| R3905 | Ro 27-3225 trifluoroacetate salt ≥98% (reversed phase HPLC), solid | Ro 27-3225 is a selective melanocortin MC4 receptor agonist. EC50 = 1 nM. Ro 27-3225 shows some activity at the MC1 receptor. Ro 27-3225 reverses hemorrhagic shock, reduces multiple organ damage, and improves survival. Ro 27-3225 may have a protective role against multiple organ failure following circulatory shock. Ro 27-3225 also reduces food intake in ob/ob mice.
| |
| |
| S4951 | Serotonin 5HT3 Receptor human membrane suspension | Membranes are suspended in 20 mM Hepes containing 150 mM NaCl and 10%sucrose, (pH 7.4 at 25 °C).
| |
| |
| S1943 | Serotonin Transporter Receptor membrane suspension | | |
| |
| T2452 | Talsaclidine ≥98% (HPLC), oil | Talsaclidine is a M1 selective muscarinic receptor agonist. Concentration-dependently, talsaclidine increases the release of APPs and dose-dependently. Talsaclidine decreases Aβ formation and decreases cerebrospinal fluid Aβ in AD patients.
| |
| |
| T8949 | Telmisartan ≥98% (HPLC), solid | Telmisartan is a non-peptide AT1 angiotensin receptor antagonist.
| |
| |
| 77965 | Tris(2-ethylhexyl)phosphine oxide Selectophore™, ≥95.0% (GC) | | |
| |
| V2015 | VU10010 ≥98% (HPLC) | VU10010 is a potent and selective allosteric M4 agonist. It potentiates the response to acetylcholine 47-fold at M4 receptors, but has no effect at other receptor subclasses. It is suspected to have even finer selectivity, operating at excitatory, but not at inhibitory, hippocampal synapses.1
| |
| |
